Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Highlights: RECCE® 327 (R327) was shown to significantly reduce SARS-CoV-2 levels in hamsters, the gold-standard in COVID-19 preclinical animal modelsNew patents lodged supporting anti-infective...
-
Highlights: Phase 1 safety and tolerability study of RECCE® 327 (R327) advancing to a Phase 1b/2a multi-dose and sepsis efficacy studyInitiating two new Phase 2 trials of R327 for the treatment of...
-
SYDNEY, Australia, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX:RCE, FSE:R9Q) (the Company) is pleased to announce the appointment of Alistair McKeough to its Board of...
-
Highlights: 10 subjects in cohort seven were intravenously dosed with RECCE® 327 at 6,000mg Independent Safety Committee reviewing cohort seven data and anticipate a recommendation to proceed to...
-
– Dr. Sutton to help advance Recce’s portfolio of infectious disease programs focused on significant unmet medical needs – SYDNEY Australia, July 12, 2022 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals...
-
Highlights: 10 subjects in cohort six intravenously dosed with RECCE® 327 at 4,000mg demonstrated good safety and tolerabilityIndependent Safety Committee to review cohort six data – anticipate...
-
Highlights: In cohort five, RECCE® 327 (R327) demonstrated good safety and tolerability in subjects intravenously dosed at 2,000mgIndependent Safety Committee approves cohort six dosing at 4,000mg;...
-
Highlights: 36 subjects successfully dosed in Phase I intravenous (IV) clinical trial of RECCE® 327 (R327) – demonstrating good safety and tolerability at 1,000mg Independent Safety Committee...
-
SYDNEY, Australia, April 12, 2022 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Limited (ASX:RCE, FSE:R9Q), the Company developing a new class of synthetic anti-infectives, is pleased to announce the...
-
Highlights: 10 subjects in cohort four intravenously dosed; RECCE® 327 at 1,000mg, indicating to be safe and well-tolerated Independent Safety Committee to review cohort four data – expect...